FGFR4 Gene Mutation clinical trials at UCSF
1 research study open to eligible people
The FGFR4 gene mutation is a change that may cause abnormal cell growth. UCSF is investigating TYRA-430 in people with liver and solid tumors to assess its safety and effectiveness. These studies look into conditions with altered FGF/FGFR signaling.
Showing trials for
Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
open to eligible people ages 18 years and up
A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary antitumor activity of TYRA-430 in cancers with FGF/FGFR pathway aberrations, including locally advanced/metastatic hepatocellular carcinoma and other advanced solid tumors.
San Francisco, California and other locations
Last updated: